Anacetrapib-driven Triglyceride Lowering Explained: the Fortuitous Role of CETP in the Intravascular Catabolism of Triglyceride-rich Lipoproteins

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2017 Apr 23

PMID 28432183

Citations 1

Authors

Amanda L Brown

J Mark Brown

Affiliations

Soon will be listed here.

Citing Articles

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?.

Filippatos T, Kei A, Elisaf M Diseases. 2017; 5(4).

PMID: 28961179 PMC: 5750532. DOI: 10.3390/diseases5040021.

References

Inazu A, Brown M, Hesler C, Agellon L, Koizumi J, Takata K . Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990; 323(18):1234-8. DOI: 10.1056/NEJM199011013231803. View

Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

Di Bartolo B, Duong M, Nicholls S . Clinical trials with cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol. 2016; 27(6):545-549. DOI: 10.1097/MOL.0000000000000352. View

Jiang X, Agellon L, Walsh A, Breslow J, Tall A . Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest. 1992; 90(4):1290-5. PMC: 443172. DOI: 10.1172/JCI115993. View

Marotti K, Castle C, Boyle T, Lin A, Murray R, Melchior G . Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993; 364(6432):73-5. DOI: 10.1038/364073a0. View

Takahashi K, Jiang X, Sakai N, Yamashita S, Hirano K, Bujo H . A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. J Clin Invest. 1993; 92(4):2060-4. PMC: 288375. DOI: 10.1172/JCI116802. View

Filippatos T, Klouras E, Barkas F, Elisaf M . Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Rev Cardiovasc Ther. 2016; 14(8):953-62. DOI: 10.1080/14779072.2016.1189327. View

Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M . Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016; 133(4):447-54. DOI: 10.1161/CIR.0000000000000366. View

SNIDERMAN A, Teng B, Vezina C, Marcel Y . Cholesterol ester exchange between human plasma high and low density lipoproteins mediated by a plasma protein factor. Atherosclerosis. 1978; 31(3):327-33. DOI: 10.1016/0021-9150(78)90067-9. View

10.

Millar J, Lassman M, Thomas T, Ramakrishnan R, Jumes P, Dunbar R . Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E. J Lipid Res. 2017; 58(6):1214-1220. PMC: 5454510. DOI: 10.1194/jlr.M074880. View

11.

Gaynor B, Sand T, Clark R, Aiello R, Bamberger M, Moberly J . Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis. 1994; 110(1):101-9. DOI: 10.1016/0021-9150(94)90073-6. View

12.

Schwartz G, Olsson A, Abt M, Ballantyne C, Barter P, Brumm J . Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22):2089-99. DOI: 10.1056/NEJMoa1206797. View

13.

Sarwar N, Sandhu M, Ricketts S, Butterworth A, Di Angelantonio E, Boekholdt S . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375(9726):1634-9. PMC: 2867029. DOI: 10.1016/S0140-6736(10)60545-4. View

14.

Voight B, Peloso G, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen M . Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012; 380(9841):572-80. PMC: 3419820. DOI: 10.1016/S0140-6736(12)60312-2. View

15.

Yamashita S, Matsuzawa Y . Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation. Curr Opin Lipidol. 2016; 27(5):459-72. DOI: 10.1097/MOL.0000000000000332. View

16.

Brown M, Inazu A, Hesler C, Agellon L, Mann C, Whitlock M . Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 1989; 342(6248):448-51. DOI: 10.1038/342448a0. View

17.

Chajek T, Fielding C . Isolation and characterization of a human serum cholesteryl ester transfer protein. Proc Natl Acad Sci U S A. 1978; 75(7):3445-9. PMC: 392794. DOI: 10.1073/pnas.75.7.3445. View

18.

Agellon L, Walsh A, Hayek T, Moulin P, Jiang X, Shelanski S . Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem. 1991; 266(17):10796-801. View

19.

Breslow J . Apolipoprotein genetic variation and human disease. Physiol Rev. 1988; 68(1):85-132. DOI: 10.1152/physrev.1988.68.1.85. View

20.

Bagdade J, Wagner J, Rudel L, Clarkson T . Accelerated cholesteryl ester transfer and altered lipoprotein composition in diabetic cynomolgus monkeys. J Lipid Res. 1995; 36(4):759-66. View